Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.
3 Spectacular High-Yield Dividend Stocks to Buy in November
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Fintel on MSN4d
Maxim Group Downgrades Gilead Sciences (GILD)
Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...
Gilead cut to Hold at Maxim on valuation
Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...
Barchart on MSN5d
Gilead Sciences Stock: Analyst Estimates & Ratings
Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market ...
Gilead increases 2024 outlook, expects new drug filing by end of year
Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...
Hold Rating for Gilead Sciences Amid Promising Yet Preliminary Anito-cel Trial Results
Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
Top 2 pharma stocks to buy amid surge in deadly fungi
Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...